Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Stocks were lower Thursday as traders weighed a greater-than-expected increase in weekly jobless claims and awaited the U.S.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...

Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...

Shares in telehealth group Hims & Hers Health (NYSE:HIMS) dropped in premarket US trading on Thursday after federal drug ...

Shares in Hims & Hers Health fell after the U.S. Food and Drug Administration said Eli Lilly's obesity and diabetes drugs are no longer in shortage. Shares were down 7% in premarket trading to $17.64.

Hims & Hers is making GLP-1 weight loss medications more accessible with a 50% discount for front-line heroes. Mihir Gandhi ...

Hims & Hers is a fantastic value despite its high on-the-surface P/E ratio and valuation metrics. Click here to read why HIMS ...

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.

S&P 500 futures are down 0.4%. Dow Jones Industrial Average futures are falling 0.4%. Nasdaq 100 futures are slipping 0.6%.